Drug firm Strides Arcolab today said it has received the US health regulator's approval to market injectable Clindamycin USP, used in the treatment of bacterial infections, in the American market.
The product will be available in three single-dose vial sizes and in pharmacy bulk packaging, Strides Arcolab said in a statement.
"The product is expected to be launched in early 2012," it said, adding that the company received approval for its Clindamycin USP from the US Food and Drug Administration (USFDA).
According to IMS data, the size of the US market for injectable Clindamycin stood at $65 million (including bags) in 2011.
Clindamycin is the twelfth product approved under a marketing tie-up between Strides and US-based Sagent Pharmaceuticals. As per the agreement, Strides will develop and supply more than 25 injectable products for the US market, which will be marketed by Sagent.
Shares of Strides Arcolab were being quoted at Rs 339.95 apiece on the BSE in late afternoon trade today, down 3.79 per cent from their previous close.
